Resveratrol for Cancer Prevention: SIRT1, p53 Activation and the Human Trial Evidence

Resveratrol — the polyphenol found in grape skins, red wine, and Japanese knotweed — was one of the first dietary compounds shown to extend lifespan in model organisms, and its cancer prevention mechanisms have been extensively studied. It activates SIRT1, inhibits NF-kB, and — uniquely among dietary compounds — directly activates p53, the genome's primary tumour suppressor. Multiple Phase I and II clinical trials have examined resveratrol in cancer patients and at-risk populations, producing an unusually detailed human pharmacological evidence base. The principal challenge is bioavailability, and understanding the implications of this shapes how resveratrol is most rationally used for cancer prevention.

Mechanism 1: p53 Tumour Suppressor Activation

p53 is the most important tumour suppressor gene in human cancer — mutated or inactivated in over 50% of all human cancers. In cells with intact p53, it continuously monitors for DNA damage and oncogenic stress, triggering cell cycle arrest and apoptosis when threats are detected. Resveratrol activates p53 through SIRT1-independent mechanisms — stabilising p53 protein, promoting its nuclear localisation, and enhancing its transcriptional activity at target gene promoters including p21, PUMA, and Bax. This p53 activation is the most distinctive feature of resveratrol's cancer prevention mechanism among all dietary compounds.

Mechanism 2: SIRT1 and Epigenetic Cancer Prevention

Resveratrol activates SIRT1 — the NAD+-dependent deacetylase central to the caloric restriction mimetic response. In the context of cancer prevention, SIRT1 activation is relevant through:

• Deacetylation and stabilisation of p53 (complementing direct p53 activation)
• Suppression of NF-kB-driven inflammatory gene expression through RelA/p65 deacetylation
• Histone deacetylase activity that can reactivate epigenetically silenced tumour suppressor genes
• Promotion of DNA repair through deacetylation of Ku70 — a protein involved in double-strand DNA break repair

Mechanism 3: NF-kB and COX-2 Inhibition

Resveratrol inhibits NF-kB activation through both IKK inhibition and direct suppression of NF-kB nuclear translocation. It also inhibits COX-2 expression — reducing PGE2 production that promotes tumour cell proliferation, immune evasion, and angiogenesis. These mechanisms address the chronic inflammatory microenvironment that enables tumour progression independently of the direct anti-proliferative effects.

Research: Phase I Colorectal Trial — Tissue Concentrations

A Phase I trial (Patel et al., 2010, University of Leicester) provided the first direct evidence that oral resveratrol reaches human tissue at biologically active concentrations. Patients with colorectal cancer resection were given resveratrol for 8 days before surgery. Resveratrol and its metabolites were detected in colorectal tissue at concentrations sufficient to reduce Wnt target gene expression and suppress cancer cell proliferation markers. Critically, the tissue concentrations achieved at 0.5g daily were similar to those active in cell studies — bridging the key pharmacokinetic gap between in vitro data and clinical relevance for colorectal cancer prevention specifically.

Research: Colorectal Cancer Biomarker RCT

A double-blind RCT (Brown et al., 2016) in 40 patients with resected colorectal cancer found that SRT501 (a micronised resveratrol formulation, 5g daily) for 14 days produced significant apoptosis induction in hepatic metastasis tissue and detectable resveratrol in liver tissue — the first evidence that resveratrol reaches liver metastases at active concentrations. Ki-67 (proliferation marker) was also significantly reduced in the hepatic metastasis samples, consistent with meaningful anti-tumour activity.

Research: Multiple Myeloma Phase II

A Phase II trial examining resveratrol in multiple myeloma patients found that SRT501 produced renal complications at the doses required for anti-myeloma activity — highlighting that very high-dose resveratrol supplementation carries risks that do not apply at prevention doses. This trial is relevant because it defines the upper dose boundary and the importance of using standard prevention doses (500mg-1g daily) rather than therapeutic doses.

Bioavailability: The Critical Issue

Standard resveratrol has poor oral bioavailability — it is rapidly conjugated (glucuronidated and sulphated) in the intestinal wall and liver, with peak plasma free resveratrol typically below 40 ng/mL after a 1g dose. However, the colorectal cancer prevention application is less dependent on systemic bioavailability because the colon achieves direct high-concentration exposure from the supplement itself — similar to the rationale for curcumin in colorectal cancer prevention. For systemic cancer prevention, enhanced formulations improve plasma delivery:

• Micronised resveratrol (SRT501): 3.6x better bioavailability than standard — the form used in the clinical trials
• Liposomal resveratrol: 2-4x improved bioavailability in preliminary studies
• With piperine: Modest bioavailability improvement through CYP3A4 and glucuronidation inhibition
• With quercetin: Synergistic — quercetin inhibits resveratrol conjugation enzymes and the two compounds share complementary mechanisms

Dosage for Cancer Prevention

• Preventive dose: 250-1,000mg resveratrol daily — the dose range associated with mechanistic activity and used in Phase I/II pharmacokinetic trials
• Form: Trans-resveratrol (not cis) — the biologically active isomer that is the form found in grapes and studied in research
• With fat: Improves absorption — take with a fat-containing meal
• Timing: Evidence suggests two divided doses (morning and evening) maintain more consistent plasma levels than a single daily dose given rapid metabolism